journal article·2017-01-02Open access

Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies

Run Wang, Yong Xu

Abstract

The aim of present study was to develop VIN-loaded mPEG-PLA nanoparticle systems. The VIN mPEG-PLA nanoparticles were prepared using an emulsion solvent evaporation method, and studied their particle size, morphology, encapsulation efficiency and drug-loading coefficient. Moreover, the nanoparticles were evaluated on the drug release behaviors in vitro and bioavailability in vivo. The results show that the spherical nanoparticles obtained were negatively charged with a zeta potential of about −23.4 mV and characterized ∼110 nm with a narrow size distribution. The encapsulation efficiency and drug loading of prepared NPs were 76.4 ± 6.3 and 9.2 ± 2.2% (n=5), respectively. The in vitro release showed that the percent of accumulated dissolution of VIN NPs in phosphate-buffered saline 6.8 over 24 h was <80%, which was almost 100% of VIN in commercial injections. The in vivo study indicated that systemic absorption of VIN was significantly enhanced by incorporating into mPEG–PLA NPs compared with VIN injection (2.87-fold in AUC0–t). The results suggested that the form of VIN in mPEG–PLA NPs could enter the body circulation to perform sustained release in vitro and in vivo.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Connective tissue disorders research · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical, 85 Hospital of People’s Liberation Army, Shanghai, China

References (35)

Show source-provided references
1. 10.1021/nn102324e10.1021/nn102324e ↗
2. 10.1016/S0361-9230(00)00354-310.1016/S0361-9230(00)00354-3 ↗
3. 10.1016/j.biomaterials.2006.04.03910.1016/j.biomaterials.2006.04.039 ↗
4. 10.1016/j.eurpolymj.2005.07.02210.1016/j.eurpolymj.2005.07.022 ↗
5. 10.1093/ajh/1.3.26210.1093/ajh/1.3.262 ↗
6. 10.1146/annurev.bioeng.8.061505.09583810.1146/annurev.bioeng.8.061505.095838 ↗
7. 10.1021/ed074p122710.1021/ed074p1227 ↗
8. 10.1016/j.biomaterials.2003.09.05510.1016/j.biomaterials.2003.09.055 ↗
9. 10.1081/AL-12000455410.1081/AL-120004554 ↗
10. 10.1039/c2cs15327k10.1039/c2cs15327k ↗
11. 10.1039/C4CP00234B10.1039/C4CP00234B ↗
12. 10.1023/A:102020082243510.1023/A:1020200822435 ↗
13. 10.1097/00004850-199100610-0000510.1097/00004850-199100610-00005 ↗
14. 10.1016/j.jconrel.2009.02.01010.1016/j.jconrel.2009.02.010 ↗
15. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
16. 10.1002/adma.20110231310.1002/adma.201102313 ↗
17. 10.1016/S0169-409X(02)00015-710.1016/S0169-409X(02)00015-7 ↗
18. 10.1016/j.jconrel.2006.01.00210.1016/j.jconrel.2006.01.002 ↗
19. 10.1016/0378-5173(90)90381-D10.1016/0378-5173(90)90381-D ↗
20. 10.1007/BF0319012010.1007/BF03190120 ↗
21. 10.1016/j.jconrel.2008.12.01810.1016/j.jconrel.2008.12.018 ↗
22. Nishiyama N · Polym Ther II · 2006 · 193 · 67
23. 10.1016/0731-7085(85)80016-910.1016/0731-7085(85)80016-9 ↗
24. 10.1007/BF0319017910.1007/BF03190179 ↗
25. 10.1002/jps.1048610.1002/jps.10486 ↗
26. 10.2147/CCID.S3955910.2147/CCID.S39559 ↗
27. 10.7314/APJCP.2014.15.2.51710.7314/APJCP.2014.15.2.517 ↗
28. 10.1021/mp200626j10.1021/mp200626j ↗
29. 10.1007/BF0054406810.1007/BF00544068 ↗
30. Szakács T · Pol J Pharmacol · 2001 · 53 · 623
31. 10.1016/S1359-6446(05)03575-010.1016/S1359-6446(05)03575-0 ↗
32. 10.1021/ja208433810.1021/ja2084338 ↗
33. 10.1016/0378-5173(90)90280-H10.1016/0378-5173(90)90280-H ↗
34. 10.1016/j.addr.2014.02.00210.1016/j.addr.2014.02.002 ↗
35. 10.1016/j.biomaterials.2004.06.02410.1016/j.biomaterials.2004.06.024 ↗